Summary
Lip cancer is a malignant disease that arises from the uncontrolled growth of cells in the lips, primarily involving squamous cell carcinoma (SCC), which accounts for approximately 90% to 95% of cases. Classified as a subset of oral cancer, lip cancer typically develops on the lower lip due to its greater sun exposure and is often associated with precancerous conditions like actinic cheilitis. Another common form, basal cell carcinoma, also occurs on sun-exposed lip areas but is less frequent. Because lip cancer often presents as visible sores or lesions that fail to heal, it is frequently detected early, contributing to a generally favorable prognosis with treatment primarily involving surgery and radiation therapy.
The disease’s risk factors include tobacco use (both smoked and smokeless), alcohol consumption, ultraviolet (UV) radiation, and human papillomavirus (HPV) infection, with regional variations in their prevalence influencing incidence rates worldwide. Tobacco remains the leading contributor globally, especially where chewing tobacco and betel quid are common, such as in parts of Asia. UV exposure is a significant factor specifically for lip SCC, highlighting the importance of sun protection measures. Despite effective treatments, disparities in healthcare access and lifestyle factors contribute to variations in incidence and mortality, with ongoing public health efforts targeting prevention through tobacco cessation, HPV vaccination, and sun protection.
Lip cancer is staged using the American Joint Committee on Cancer (AJCC) TNM system, which assesses tumor size, lymph node involvement, and metastasis to guide prognosis and treatment planning. Early-stage lip cancers often have a high cure rate, while advanced stages involving lymph nodes or distant spread have poorer outcomes. Histopathological grading and emerging molecular markers continue to refine diagnostic accuracy and prognostic assessments, although controversies remain regarding the optimal grading systems and the role of adjunct therapies in advanced disease.
Research efforts focus on improving early detection, refining treatment techniques such as Mohs micrographic surgery, and understanding the complex interplay of risk factors globally. Public health initiatives emphasize reducing tobacco and alcohol use, promoting HPV vaccination, and encouraging sun protection to decrease the incidence of lip cancer worldwide. Despite these advances, lip cancer remains a significant health concern, particularly in regions with high exposure to known carcinogens and limited healthcare resources.
Overview
Lip cancer is a type of head and neck cancer that originates when the cells forming the lip begin to grow uncontrollably, leading to the development of lesions or tumors. It is classified as a form of oral cancer, primarily arising from the squamous cells that line the lips and other oral and facial structures such as the tongue, cheeks, and throat. Squamous cell carcinoma (SCC) represents the majority of lip cancer cases, accounting for approximately 90% to 95% of all oral malignancies, with many SCCs of the lips emerging from actinic cheilitis (AC), a precancerous condition characterized by pale, dry, scaly lips, chronic ulcerations, and other changes in the vermillion border of the lip. Another common type of lip cancer is basal cell carcinoma, which typically develops on sun-exposed areas of the skin due to ultraviolet (UV) radiation exposure. Lip cancer often appears as a persistent mouth sore or an area of discolored skin that fails to heal. The disease has a relatively high survival rate because it is frequently diagnosed at an early stage and is effectively treated, often with surgery.
The staging and classification of lip cancer involve assessing tumor size, lymph node involvement, and metastasis categories (T, N, and M), which are then combined in a process called stage grouping based on the American Joint Committee on Cancer (AJCC) system, updated as of January 2018. Incidence and mortality data for lip cancer vary globally, with estimates compiled through methods such as those used by GLOBOCAN, which rely on the best available regional and national cancer data to provide comprehensive profiles. Treatment options depend on several factors including the cancer stage, patient health, and individual preferences, and often involve a combination of therapies planned in collaboration with healthcare providers.
Causes and Risk Factors
Lip cancer, a subtype of oral cancer, is influenced by a variety of environmental, lifestyle, and infectious factors. Tobacco use remains the principal risk factor globally, with both smoked and smokeless forms contributing significantly to the incidence of lip and oral cavity cancers (LOCC). Smoking tobacco introduces carcinogens directly into the respiratory tract and bloodstream, while smokeless tobacco comes into direct contact with the oral mucosa, causing localized damage. The mode of tobacco consumption varies regionally; in Western countries, smoked tobacco predominates, whereas in parts of southern Asia, including India and Sri Lanka, chewing tobacco often combined with betel quid and areca nut is common and associated with high cancer rates.
Alcohol consumption is another major risk factor, frequently acting synergistically with tobacco to elevate cancer risk in the oral cavity and oropharyngeal regions. Ethanol, present in all alcoholic beverages, contributes to carcinogenesis, and no alcoholic drink has been found to be safer than others in terms of cancer risk. Public health guidelines emphasize moderation in alcohol intake to reduce such risks.
Human papillomavirus (HPV), particularly high-risk strains, plays an increasing role in oropharyngeal cancers and is associated with a better prognosis in HPV-positive cases compared to HPV-negative ones. The prevalence of HPV-related oral cancers is highest in North America, followed by Asia, Oceania, and Europe, and lowest in Latin America and the Caribbean.
Ultraviolet (UV) radiation exposure is a significant risk factor specifically for lip squamous cell carcinoma, with prolonged sun exposure and inadequate protection leading to higher incidence rates. Protective measures such as using SPF lip balms and avoiding excessive sun exposure are recommended to mitigate this risk.
Other contributing factors include secondhand smoke, which contains high concentrations of carcinogens similar to those in primary cigarette smoke, and is linked to increased risk of oral and lip cancers, even among non-inhalers such as cigar and pipe smokers. Poor oral hygiene and genetic predispositions also play roles, though lifestyle factors like tobacco and alcohol use typically have a greater impact.
Demographically, lip cancer is more common in individuals over the age of 55, with men being more frequently affected than women. Socioeconomic status, measured by the Human Development Index (HDI), correlates positively with LOCC incidence and mortality, likely reflecting variations in tobacco use prevalence and healthcare access across regions.
Signs and Symptoms
Early signs of lip cancer often present as a lump, sore, blister, ulcer, or persistent lesion on the lips or inside the mouth that fails to heal within two weeks or partially heals and then recurs. These lesions most commonly affect the lower lip but can occur on either the upper or lower lip. Because the lips are highly visible, lip cancer is frequently detected in its early stages, allowing for timely diagnosis and treatment.
Symptoms can be subtle and may be mistaken for benign conditions such as cold sores, which typically resolve within about ten days, whereas cancerous lesions persist or worsen. In addition to non-healing sores, patients might experience pain, bleeding, or swelling in the affected area. The surface of the lips may appear pale, dry, scaly, or show chronic ulcerations and erosions, sometimes accompanied by blurring of the vermillion border and a sandpaper-like texture upon palpation. Patients often report a stinging, burning, or tight sensation in the lip.
The appearance of lip cancer can vary depending on the cancer type and the individual’s skin tone. For example, squamous cell carcinoma (SCC), which accounts for approximately 90–95% of lip cancers, often develops from actinic cheilitis (AC), a precancerous condition characterized by chronic lip changes such as scaling and atrophy. Basal cell carcinoma (BCC), a less common form, tends to occur on the skin of the upper lip rather than the vermillion border.
Other malignancies that can affect the lip area include mucosal melanoma, which arises from pigment-producing melanocytes, lymphoma involving immune cells, and minor salivary gland cancers such as adenoid cystic carcinoma and mucoepidermoid carcinoma. It is important to differentiate lip cancer from other conditions that may mimic its symptoms, including inflammatory disorders like eczema, leukoplakia, lichen planus, granulomatous cheilitis, and infections such as primary syphilis, which can present as painless ulcers without bleeding.
Due to the similarity of symptoms with other diseases and the possibility of systemic conditions manifesting as pigmented spots or lip lesions, any unexplained or persistent changes in the lips or mouth area should prompt medical evaluation. Early recognition and consultation with healthcare professionals are critical to ensuring appropriate diagnosis and management.
Diagnosis
The diagnosis of lip cancer typically begins with a thorough clinical examination, including an assessment of the oral cavity and surrounding tissues. Providers may observe various presentations such as pale, dry, scaly lips, chronic ulcerations, erosions, blurring of the vermillion-skin border, and vermillion atrophy. Patients often report symptoms like stinging, burning, or a tight sensation in the lip area, and palpation may reveal a fine sandpaper-like texture. Given the wide range of clinical appearances, the differential diagnosis includes inflammatory disorders such as eczema, benign leukoplakia, lichen planus, granulomatous cheilitis, and xerosis with chronic irritation.
A definitive diagnosis requires tissue sampling, with biopsy being the gold standard. During a biopsy, a small tissue sample is taken from the affected area under local anesthesia and sent to a laboratory for histopathological examination. This process enables pathologists to identify the presence and type of cancer cells, crucial for confirming lip cancer and distinguishing it from other lesions. Immunohistochemistry (IHC) may also be employed to assist in diagnosis, particularly in complex cases where differentiation from other neoplasms is challenging; IHC antibodies can enhance dermatopathological evaluation beyond routine hematoxylin and eosin staining.
Following biopsy confirmation, additional tests are conducted to determine the cancer’s stage and whether it has spread. These may include imaging studies, endoscopy, and further tissue sampling as needed. Staging is critical in guiding treatment decisions and prognosis and is commonly performed using the American Joint Committee on Cancer (AJCC) TNM system, which evaluates tumor size (T), lymph node involvement (N), and metastasis (M). The stage of lip cancer ranges from I to IV, with stage I representing early, localized disease and stage IV indicating advanced spread.
Histopathological grading systems are also used to assess the tumor’s aggressiveness and potential behavior. While the World Health Organization (WHO) endorses a simple, differentiation-based grading system for oral squamous cell carcinoma (OSCC), its prognostic value is limited as it does not consider factors such as tumor growth pattern, stromal reaction, or tumor-stroma ratio. More nuanced grading systems, such as those developed by Jakobsson and modified by Anneroth and Hansen, incorporate multiple morphological criteria to better evaluate malignancy potential in head and neck squamous cell carcinomas. Emerging molecular markers like MMP1 have shown promise in improving tumor detection and diagnostic accuracy.
Staging
The staging of lip cancer is a critical step in determining prognosis and guiding treatment decisions. The most commonly used system is the American Joint Committee on Cancer (AJCC) TNM system, which evaluates three key components: the size and extent of the primary tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). These categories are combined through a process called stage grouping to assign an overall stage to the cancer, facilitating a standardized assessment of disease severity and outlook.
The AJCC staging system has undergone revisions to improve its predictive accuracy, such as the 7th edition update for cutaneous squamous cell carcinoma (cSCC), which includes lip cancers. This revision has been shown to be effective in predicting risks such as local recurrence and subsequent metastasis, particularly in high-risk groups like transplant recipients, although further validation in the general population remains necessary. Tumors are staged based on size criteria, nodal involvement, and extent of invasion into adjacent structures. For instance, stage 3 lip cancer generally refers to tumors larger than 4 centimeters or those with lymph node involvement, while stage 4 encompasses more extensive local invasion into bones, nerves, or surrounding tissues, with multiple substages defining the severity of spread.
Histopathologic grading systems also play a role in characterizing lip cancer, with the World Health Organization (WHO) endorsing a differentiation-based system despite its limited prognostic value. More detailed grading approaches, such as Anneroth’s system, evaluate multiple morphological and invasion parameters, correlating better with outcomes like lymph node metastasis compared to simpler systems such as Broder’s, which focuses solely on cellular differentiation.
Early-stage lip cancers (stage I and II) generally have a favorable prognosis and can often be cured with surgery or radiation therapy. However, factors such as positive surgical margins or a tumor depth exceeding 5 millimeters significantly increase the risk of local recurrence. Additionally, the risk of occult nodal metastasis escalates with greater depth of invasion, underscoring the importance of careful staging and assessment in treatment planning.
Lymph node metastasis in lip cancer occurs less frequently in well-differentiated tumors compared to undifferentiated ones (5% versus 20%), and the overall incidence of metastasis varies widely between 0.5% and 16%. These clinical and histopathological criteria help identify patients at higher risk who may benefit from elective neck dissection or more aggressive management.
Treatment
Treatment options for lip cancer primarily depend on the stage and size of the tumor, with early detection significantly improving the prognosis. The standard therapy usually involves a combination of surgery and radiation therapy, aiming to remove the tumor while preserving the function and appearance of the lips. Because lip cancer is often noticed early due to its visible location, patients are commonly diagnosed at stages when treatment is most effective.
Surgery is generally preferred for small cancers that can be fully excised. Techniques such as Mohs micrographic surgery, surgical stripping, or thin resection are commonly used to remove the cancerous tissue along with a margin of healthy tissue to ensure complete removal. For carcinoma in situ that recurs after surgery, radiation therapy may be employed as an additional treatment. Larger or deeper tumors often require surgery followed by reconstructive procedures to restore lip function and appearance.
Radiation therapy, which uses high-energy beams to kill tumor cells and prevent recurrence, can also be used alone, especially in cases where surgery is not feasible or as an adjunct to surgery. Studies indicate that surgery and radiation therapy produce similar cure rates in early-stage lip cancers, with the choice of treatment guided by considerations of cosmetic and functional outcomes, as well as patient preference.
For patients with more advanced stages (stage III and IV), treatment typically involves a combination of surgery and radiation therapy to maximize local control and survival. Chemotherapy combined with radiation (chemoradiation) may be considered as an additional modality in certain cases, although surgery and radiation remain the cornerstone of treatment.
Follow-up care is critical to monitor for recurrence, as timely detection of any returning cancer can improve long-term outcomes. Ongoing clinical trials continue to explore new treatments to improve cure rates and reduce side effects for patients with lip cancer.
Prevention
Preventing lip cancer involves a combination of lifestyle modifications, protective measures, and public health initiatives aimed at reducing exposure to known risk factors. The most effective step in prevention is avoiding tobacco use in all forms, as tobacco consumption—whether smoked or smokeless—is the primary risk factor for oral cancers, including lip cancer. Limiting alcohol intake also plays a significant role, since alcohol can influence hormone levels that promote cell division, increasing the likelihood of cancer development.
Sun protection is crucial in preventing lip cancer because prolonged ultraviolet (UV) radiation exposure is a well-established carcinogen for the lips. Protective measures include using lip balms with SPF, wearing wide-brimmed hats, and avoiding
Prognosis
Lip cancer generally has a favorable prognosis, particularly when detected and treated early. The overall 5-year survival rate is approximately 91%, reflecting the advantage of the cancer’s visible location, which often leads to earlier detection compared to other cancers. However, survival rates decline significantly if the cancer spreads: 5-year survival drops to 63% when it invades nearby tissues and to 38% if distant metastases occur.
The prognosis is influenced by several factors, including the stage and grade of the tumor. High-grade lip squamous cell carcinoma (SCC) in advanced stages is associated with a poor outcome. Staging based on the TNM system helps determine how advanced the cancer is, guiding treatment decisions and prognostic assessments. Early-stage cancers confined to the superficial layers (Stage 0) have better outcomes, whereas tumors larger than 4 centimeters or those with lymph node involvement (Stage 3) carry a worse prognosis. Involvement of surrounding structures such as bone or nerves, as seen in Stage 4A, further diminishes survival prospects.
Recurrence remains a concern even after successful treatment. Rapid recurrence after tumor removal often indicates a poorer prognosis. Lymph node metastasis in lip cancer occurs in less than 20% of patients, with well-differentiated carcinomas showing a lower rate of metastasis (around 5%) compared to undifferentiated forms (up to 20%). Surgical removal of tumors at early stages generally allows effective reconstruction and better functional outcomes.
Additionally, prognostic evaluation tools such as the BD model have proven useful in assessing outcomes for patients with lip SCC. Histopathological and molecular factors, including proliferation markers and stromal interactions, are areas of ongoing research aiming to refine prognostic predictions, although current grading systems have limitations and often do not fully incorporate these factors.
Epidemiology
Lip cancer, along with cancers of the oral cavity and pharynx, presents a varied epidemiological pattern influenced by geographic, demographic, and behavioral factors. Globally, the incidence of lip and oral cavity cancer (LOCC) is highest in regions such as Oceania and Asia, areas with a history of high tobacco use in its various forms, including smoking and chewing tobacco, often combined with betel quid consumption—a recognized major risk factor for potentially malignant lesions and oral cancers. Southeast Asian countries notably exhibit a higher incidence of LOCC, correlating with the widespread use of betel nut.
The global burden of tobacco- and alcohol-attributable early-onset lip and oral cavity cancer (LOC) and other pharyngeal cancers (OPC) has been characterized by distinct trends. Between 1990 and 2019, most regions experienced declines in age-standardized mortality rates (ASMR) and disability-adjusted life years (DALYs) related to these cancers; however, certain regions such as East and South Asia, Western Sub-Saharan Africa, and Eastern Europe showed increasing trends in ASMR and ASDR (age-standardized disability adjusted life years rate). In 2019, tobacco- and alcohol-attributable early-onset OPC caused an estimated 8,402 deaths and approximately 386,418 DALYs globally.
Projections indicate that the incidence of lip, oral cavity, and pharyngeal cancers will rise substantially in the coming decades. Using population projections and fixed cancer incidence rates from 2012, estimates suggest a 62% increase in new cases worldwide—from approximately 529,500 cases currently to around 856,000 by 2035—primarily due to demographic changes such as population growth and aging. The highest incidence remains concentrated in regions with high tobacco use and specific carcinogenic exposures. For example, nasopharyngeal cancers are most common in northern Africa and eastern/southeast Asia, reflecting a combination of genetic susceptibility, Epstein-Barr virus infection, and environmental carcinogens such as nitrosamines and salted foods.
In the United States, the lifetime risk of developing lip cancer is relatively low, with approximately 0.1% of men and women expected to be diagnosed at some point in their lives based on recent data. However, these population-level statistics cannot precisely predict individual outcomes. The overall survival rates are influenced by factors including stage at diagnosis and access to healthcare.
The epidemiology of lip cancer is also shaped by socioeconomic status and public health initiatives. Higher incidence and mortality rates are often observed in regions with limited access to preventive measures and healthcare services. Lifestyle factors, including tobacco and alcohol use, remain the predominant modifiable risks worldwide, underscoring the importance of targeted interventions. These include tobacco cessation programs, reduction of alcohol consumption, HPV vaccination, and lifestyle modifications such as maintaining a diet rich in fruits and vegetables and reducing sun exposure to the lips.
Research and Developments
Recent research has highlighted significant geographical variations in the incidence of lip and oral cavity cancers (LOCC), with the highest rates observed in countries across Oceania and Asia. This distribution correlates strongly with historical patterns of tobacco use, including various forms of smokeless tobacco, as well as the consumption of betel nut, which is recognized as a major risk factor for potentially malignant lesions and oral cancers. In particular, Southeast Asian countries exhibit higher LOCC incidence rates aligned with the geographical prevalence of betel nut chewing. However, the complexity of risk factors such as differing modalities of tobacco use (e.g., betel quid with tobacco or areca nut) across regions necessitates further comprehensive studies to clarify these relationships.
Efforts to improve understanding and management of lip cancer have also focused on histopathological grading systems, which are critical for assessing disease progression and guiding treatment strategies. Correlations between histopathologic criteria and clinical outcomes in lip squamous cell carcinoma have been examined to refine prognostic assessments and tailor therapeutic interventions more effectively.
Treatment advancements include surgical techniques aimed at complete tumor excision while preserving lip function and appearance, complemented by radiation therapy to eradicate residual cancer cells and reduce recurrence risk. Despite these approaches, preventing lip cancer remains challenging, underscoring the need for ongoing research into novel therapies. Clinical trials continue to explore new treatment modalities, offering hope for improved patient outcomes.
Diagnostic improvements have also been pivotal in enhancing treatment planning. Comprehensive testing protocols facilitate accurate staging of lip and oral cavity cancers, enabling personalized treatment decisions and optimizing the chances of successful cure. Furthermore, the emphasis on prevention and early detection remains paramount, as late-stage diagnosis significantly contributes to the high mortality associated with oral cancers worldwide. Public health strategies targeting tobacco cessation and reducing betel nut consumption are essential components of ongoing efforts to curb the global burden of these malignancies.
The content is provided by Blake Sterling, Lifelong Health Tips
